Product Description
ASP7991 is a calcimimetic that acts on the calcium-sensing receptor on parathyroid cell membranes and suppresses parathyroid hormone (PTH) secretion in the treatment of secondary hyperparathyroidism.
Mechanisms of Action: CaSR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Astellas Pharma
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hyperparathyroidism, Secondary
Phase 1: Healthy Volunteers|Kidney Failure, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01872026 |
7991-CL-1003 | P1 |
Completed |
Kidney Failure, Chronic |
2013-06-26 |
2019-03-19 |
Treatments |
|
NCT01872013 |
7991-CL-1002 | P1 |
Completed |
Healthy Volunteers |
2013-02-01 |
2019-03-19 |
Treatments |
|
NCT01675518 |
7991-CL-0001 | P1 |
Completed |
Healthy Volunteers |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT02133404 |
7991-CL-1004 | P2 |
Completed |
Hyperparathyroidism, Secondary |
2014-11-10 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|